NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Dec 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α). SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to…
Pharmacologic Class:
Hematopoietic Stem Cell Mobilizer
Clinical Trials (5)
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
Started Jun 2022
1 enrolled
Sickle Cell Disease
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients
Started Oct 2021
53 enrolled
Autologous Haematopoietic Stem Cell Transplant
Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer
Started Nov 2020
25 enrolled
Metastatic Pancreatic Cancer
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Started Dec 2018
21 enrolled
GlioblastomaGlioblastoma With Primitive Neuronal ComponentGliosarcoma+2 more
Quantitating the Impact of Plerixafor
Started Aug 2015
12 enrolled
Transplants and Implants